Literature DB >> 14742653

Incidence of oral lesions in HIV-1-infected women: reduction with HAART.

D Greenspan1, S J Gange, J A Phelan, M Navazesh, M E A F Alves, L A MacPhail, R Mulligan, J S Greenspan.   

Abstract

Few studies assess the effectiveness of HAART on reducing the incidence and recurrence of oral lesions. We investigated such changes among 503 HIV+ women over six years in the Women's Interagency HIV Study. The incidence of erythematous candidiasis (EC), pseudomembranous candidiasis (PC), hairy leukoplakia (HL), and warts was computed over follow-up visits after HAART initiation compared with before HAART initiation. Analysis of our data demonstrates a strong decrease in candidiasis after HAART initiation. The incidence of EC fell to 2.99% from 5.48% (RR 0.545); PC fell to 2.85% from 6.70% (RR 0.425); and EC or PC fell to 3.43% from 7.35% (RR 0.466). No changes were seen in HL or warts. Higher HIV-RNA was associated with greater incidence of candidiasis and HL, but not warts. Analysis of these data indicates that recurrence and incidence of candidiasis are reduced by HAART, and that recurrence is reduced independently of CD4 and HIV-RNA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742653     DOI: 10.1177/154405910408300212

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  32 in total

1.  Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa.

Authors:  Denise Evans; Mhairi Maskew; Ian Sanne
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-03

2.  Supernatants from oral epithelial cells and gingival fibroblasts modulate human immunodeficiency virus type 1 promoter activation induced by periodontopathogens in monocytes/macrophages.

Authors:  O A González; J L Ebersole; C B Huang
Journal:  Mol Oral Microbiol       Date:  2010-04       Impact factor: 3.563

Review 3.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

Review 4.  Epstein-Barr virus in the pathogenesis of oral cancers.

Authors:  J T Guidry; C E Birdwell; R S Scott
Journal:  Oral Dis       Date:  2017-04-18       Impact factor: 3.511

Review 5.  Microbiome in human immunodeficiency virus infection.

Authors:  January T Salas; Theresa L Chang
Journal:  Clin Lab Med       Date:  2014-09-18       Impact factor: 1.935

6.  Oral and systemic health correlates of HIV-1 shedding in saliva.

Authors:  M Navazesh; R Mulligan; N Kono; S K S Kumar; M Nowicki; M Alves; W J Mack
Journal:  J Dent Res       Date:  2010-07-29       Impact factor: 6.116

7.  The association between oral disease and type of antiretroviral therapy among perinatally HIV-infected youth.

Authors:  Caroline H Shiboski; Tzy-Jyun Yao; Jonathan S Russell; Mark I Ryder; Russell B Van Dyke; George R Seage; Anna-Barbara Moscicki
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

Review 8.  Overview of the oral HIV/AIDS Research Alliance Program.

Authors:  C H Shiboski; J Y Webster-Cyriaque; M Ghannoum; J S Greenspan; D Dittmer
Journal:  Adv Dent Res       Date:  2011-04

9.  Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children.

Authors:  Luciana Pomarico; Daniella Ferraz Cerqueira; Rosangela Maria de Araujo Soares; Ivete Pomarico Ribeiro de Souza; Gloria Fernanda Barbosa de Araujo Castro; Sigmund Socransky; Anne Haffajee; Ricardo Palmier Teles
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-08

10.  Epithelial maturation and molecular biology of oral HPV.

Authors:  Liviu Feller; Razia Ag Khammissa; Neil H Wood; Johan Lemmer
Journal:  Infect Agent Cancer       Date:  2009-11-25       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.